James Lousararian, JD
Managing Director

Jim Lousararian, JD, joined BioVentures Investors as a Managing Director in 2017, after previously being involved with multiple BioVentures Investors portfolio companies. He brings over 20 years of entrepreneurship in the life sciences and healthcare sectors.

Jim has cultivated a career as a serial entrepreneur, including having been a co-founder and/or CEO of four life sciences start-ups, including three BioVentures portfolio companies: Verax Biomedical, where he remains as CEO; AngioLink, which sold to Medtronic in 2004; and Spirus, which was sold to Olympus in 2011. In addition, Jim was also a Co-founder of ArthroSurface Incorporated, which was acquired by Anika Therapeutics in 2020, and co-founded Nursery Products, which was sold to Synagro, in the environmental services area.

Prior to the founding of AngioLink, Jim was a part of the management team of Thermo Electron that was instrumental in building their environmental services and remediation businesses and who took Thermo ReTec Corp. public on the American Stock Exchange in 1993. While at Thermo ReTec, Jim was President of two major environmental subsidiaries and responsible for sales and marketing and business development. In addition, he led three turnarounds of troubled divisions. Jim started at Thermo as Associate General Counsel. Jim currently serves as CEO of Verax Biomedical and on the Board of Directors for Verax, Triopsy Medical and Unified Information Devices. Jim previously served on the Board of CareSignal prior to its acquistion in Q4 2021.

Jim just completed a term as President of the Board of Trustees of the Wheeler School in Providence, Rhode Island. He began his career at Hale and Dorr (now Wilmer Hale), a Boston law firm, and was previously an advisor to Point Judith Capital.

He holds a BBA degree in accounting from the University of Massachusetts, Amherst and a JD from the University of Chicago.